Invitae Corporation (NVTA): Price and Financial Metrics
NVTA Price/Volume Stats
Current price | $0.02 | 52-week high | $0.02 |
Prev. close | $0.02 | 52-week low | $0.02 |
Day low | $0.02 | Volume | 6,533,000 |
Day high | $0.02 | Avg. volume | 0 |
50-day MA | $0.00 | Dividend yield | N/A |
200-day MA | $0.00 | Market Cap | 5.21M |
NVTA Stock Price Chart Interactive Chart >
NVTA POWR Grades
- Growth is the dimension where NVTA ranks best; there it ranks ahead of 84.82% of US stocks.
- NVTA's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
- NVTA's current lowest rank is in the Stability metric (where it is better than 11.82% of US stocks).
NVTA Stock Summary
- NVTA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.2 -- higher than only 2.82% of US-listed equities with positive expected earnings growth.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -4.68 for INVITAE CORP; that's greater than it is for only 3.75% of US stocks.
- INVITAE CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 82.33%, greater than the shareholder yield of 97.77% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to INVITAE CORP, a group of peers worth examining would be DM, RIOT, COMM, SSRM, and AMWL.
- Visit NVTA's SEC page to see the company's official filings. To visit the company's web site, go to www.invitae.com.
NVTA Valuation Summary
- NVTA's price/earnings ratio is -0.1; this is 100.34% lower than that of the median Healthcare stock.
- NVTA's price/earnings ratio has moved up 20.2 over the prior 108 months.
Below are key valuation metrics over time for NVTA.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NVTA | 2023-12-29 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA | 2023-12-28 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA | 2023-12-27 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA | 2023-12-26 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA | 2023-12-22 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA | 2023-12-21 | 0.4 | -0.2 | -0.1 | -1.1 |
NVTA Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 100.6%.
- Its 5 year cash and equivalents growth rate is now at 100.6%.
- The year over year net income to common stockholders growth rate now stands at 26.38%.
The table below shows NVTA's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 519.97 | -586.852 | -3,211.6 |
2022-06-30 | 500.829 | -623.202 | -3,108.62 |
2022-03-31 | 480.519 | -617.838 | -451.373 |
2021-12-31 | 460.449 | -559.815 | -379.006 |
2021-09-30 | 434.759 | -497.479 | -408.22 |
2021-06-30 | 389.092 | -394.593 | -312.946 |
NVTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVTA has a Quality Grade of D, ranking ahead of 13.88% of graded US stocks.
- NVTA's asset turnover comes in at 0.118 -- ranking 73rd of 81 Healthcare stocks.
- BKD, VCYT, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.
The table below shows NVTA's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.118 | 0.281 | -0.331 |
2021-03-31 | 0.139 | 0.268 | -0.887 |
2020-12-31 | 0.183 | 0.291 | -1.070 |
2020-09-30 | 0.284 | 0.321 | -0.721 |
2020-06-30 | 0.280 | 0.347 | -0.790 |
2020-03-31 | 0.336 | 0.429 | -0.705 |
Invitae Corporation (NVTA) Company Bio
Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.
Latest NVTA News From Around the Web
Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain StockInvitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. |
Invitae Layoffs 2023: What to Know About the Latest NVTA Job CutsInvitae layoffs are a hot topic on Friday after the genetics company announced a 15% reduction of its workforce to reduce costs. |
Why Are Chinese Stocks Up Today?Chinese stocks are up on Friday as investors react to recent economic data that includes signs of recovering in the reigon. |
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost CutsInvitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The company has divested the assets of Ciitizen and announced strategic cost cuts, which will include a workforce reduction and other operating expense reductions. |
What Makes Invitae (NVTA) a New Buy StockInvitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
NVTA Price Returns
1-mo | N/A |
3-mo | -96.81% |
6-mo | -96.70% |
1-year | -98.39% |
3-year | -99.94% |
5-year | -99.91% |
YTD | -96.81% |
2023 | -66.30% |
2022 | -87.82% |
2021 | -63.48% |
2020 | 159.21% |
2019 | 45.84% |
Continue Researching NVTA
Want to do more research on Invitae Corp's stock and its price? Try the links below:Invitae Corp (NVTA) Stock Price | Nasdaq
Invitae Corp (NVTA) Stock Quote, History and News - Yahoo Finance
Invitae Corp (NVTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...